New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers

NCT ID NCT04930432

Recruiting now Disease control Sponsor: Betta Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated Jun 22, 2026 · Updated 13 times

Summary

This study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met) to block tumor growth. The trial aims to find the safest dose and see if the drug can shrink tumors. About 400 participants will be enrolled across multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Affiliated Hospital of Hebei University
RECRUITING

Baoding, China
Army Medical Center of PLA
RECRUITING

Chongqing, China
Beijing Cancer Hospital
RECRUITING

Beijing, China
Beijing Friendship Hospital, Capital Medical University
RECRUITING

Beijing, China
Beijing Tongren Hospital
RECRUITING

Beijing, China
Cancer Hospital affiliated to Harbin Medical University
RECRUITING

Ha’erbin, China
Cancer Hospital of Chinese Academy of Medical Sciences Shenzhen Hospital
RECRUITING

Shenzhen, China
Cancer Hospital of Shantou University Medical College
RECRUITING

Shantou, China
Cancer Hospital of The University of Chinese Academy of Sciences
RECRUITING

Hangzhou, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China
Cangzhou Hospital of Integrated TCM-WM·Hebei
RECRUITING

Cangzhou, China
Chifeng Municipal Hospital
RECRUITING

Chifeng, China
China-Japan Union Hospitai Of Jilin University
RECRUITING

Ch’ang-ch’un, China
Chongqing University Cancer Hospital
RECRUITING

Chongqing, China
First Affiliated Hospital Of Gannan Medical University
RECRUITING

Ganzhou, China
First Hospital of Qinhuangdao
RECRUITING

Qinhuangdao, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, China
Fuzhou Pulmonary Hospital of Fujian
RECRUITING

Fuzhou, China
General Hospital of Eastern Theater Command
RECRUITING

Nanjing, China
General Hospital of Tianjin Medical University
RECRUITING

Tianjin, China
Guangdong Province Traditional Chinese Medical Hospital
RECRUITING

Guangzhou, China
Guangxi Medical University Cancer Center
RECRUITING

Nanning, China
Hanzhong Central Hospital
RECRUITING

Hanzhong, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, China
Harbin Medical University cancer hospital
RECRUITING

Ha’erbin, China
He Nan Cancer Hospital
RECRUITING

Zhengzhou, China
Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)
RECRUITING

Henan, China
Henan Provincial People's Hospital
RECRUITING

Zhengzhou, China
Henan Provincial People's Hospital
RECRUITING

Zhenzhou, China
Hospital of Ningxia Medical University
RECRUITING

Yinchuan, China
Hubei Cancer Hospital
RECRUITING

Wuhan, China
Hunan Cancer Hospital
RECRUITING

Changsha, China
Inner Mongolia People's Hospital
RECRUITING

Hohhot, China
Ji Lin Cancer Hospital
RECRUITING

Changchun, China
Jiangsu Cancer Hospital
RECRUITING

Nanjing, China
Jiangsu Province Hospital
RECRUITING

Nanjing, China
Jiangxi Cancer Hospital
RECRUITING

Nanchang, China
Jiangxi cancer hospital
RECRUITING

Jiangxi, China
Liaoning Cancer Hospital
RECRUITING

Shenyang, China
Liaoning Cancer Hospital & Institute
RECRUITING

Shenyang, China
Nanjing Drum Tower Hospital
RECRUITING

Nanjing, China
Nantong Tumor Hospital
RECRUITING

Nantong, China
Peking University International Hospital
RECRUITING

Beijing, China
Qingdao Central Hospital
RECRUITING

Qingdao, China
Renmin Hospital of Wuhan University/Hubei General Hospital
RECRUITING

Wuhan, China
Shandong Cancer Hospital & institute
RECRUITING

Jinan, China
ShangHai Chest Hospital
RECRUITING

Shanghai, China
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
RECRUITING

Shanghai, China
Shanxi Provincial Cancer Hospital
RECRUITING

Taiyuan, China
Shenzhen People's Hospital
RECRUITING

Shenzhen, China
Sichuan Cancer Hospital
RECRUITING

Chengdu, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, China
Taizhou Hospital of Zhejiang Province
RECRUITING

Taizhou, China
The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of China
RECRUITING

Fuzhou, China
The Affiliated Hospital of Qingdao University
RECRUITING

Qingdao, China
The Fifth Medical Center of PLA Ceneral Hospital
RECRUITING

Beijing, China
The First Affiliated Hospital Of Xiamen University
RECRUITING

Xiamen, China
The First Affiliated Hospital of Bengbu Medical College
RECRUITING

Bengbu, China
The First Affiliated Hospital of Bengbu Medical University
RECRUITING

Bengbu, China
The First Affiliated Hospital of Dalian Medical University
RECRUITING

Dalian, China
The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, China
The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital)
RECRUITING

Wuhu, China
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, China
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xi'an, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, China
The First Hospital of China Medical University
RECRUITING

Shenyang, China
The First Hospital of Jilin University
RECRUITING

Jilin City, China
The First Hospital of Lanzhou University
RECRUITING

Lanzhou, China
The Frist Affiliated Hospital of Guangzhou Medical College
RECRUITING

Guangzhou, China
The No. 2 People's Hospital of Yibin Sichuan
RECRUITING

Yibin, China
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, China
The Second Hospital of Anhui Medical University
RECRUITING

Hefei, China
The Second Xiangya Hospital of Central South University
RECRUITING

Changsha, China
The Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, China
Tonghua Central Hospital
RECRUITING

Tonghua, China
Union Hospital, Tongji Medical College Huazhong University of Science and Technolog
RECRUITING

Wuhan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, China
Weifang People's Hospital
RECRUITING

Weifang, China
West China Hospital, Sichuan University
RECRUITING

Chengdu, China
Xiangya Hospital of Central South University
RECRUITING

Changsha, China
Xuzhou Central Hospital
RECRUITING

Xuzhou, China
Yantai Yuhuangding Hospital
RECRUITING

Yantai, China
Yunnan Cancer Hospital
RECRUITING

Kunming, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, China
Zhongnan Hospital Affiliated to Wuhan University
RECRUITING

Wuhan, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MCLA-129 (a bispecific antibody that targets two cancer-related proteins, EGFR and c-Met)

What this could lead to

If successful, this could provide a new treatment option for people with advanced solid tumors who have run out of standard therapies.

What could go wrong

This is an early-phase trial (Phase I/II) with a small number of participants, so the drug may not prove effective or may cause significant side effects. It is not yet known if it will work better than existing treatments.

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm gastric adenocarcinoma gastroesophageal junction adenocarcinoma head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER HEAD AND NECK CANCER NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER SOLID TUMOR